<DOC>
	<DOCNO>NCT01938378</DOCNO>
	<brief_summary>To assess safety tolerability octaplas™ pediatric population monitor serious adverse drug reaction , adverse drug reaction ( ADRs ) , thrombotic event ( TEs ) , thromboembolic event ( TEEs ) measure safety laboratory parameter .</brief_summary>
	<brief_title>Octaplas Pediatric Plasma Exchange Trial</brief_title>
	<detailed_description />
	<criteria>1 . Patients therapeutic plasma exchange require . 2 . Patient male female ≥ 4 year ≤ 20 year age . 3 . Patient must minimum 15 kg require RBC prim his/her plasma exchange machine . 4 . Patient patient 's legal representative ( ) /guardian ( ) /have give voluntarily write sign informed consent studyrelated procedure perform . If child old enough ( age usually deem institution ) understand risk benefit study , also inform provide write assent . 1 . Patient know homozygous congenital deficiency Protein S. 2 . Patient history severe hypersensitivity reaction plasmaderived product excipient investigational product . 3 . Patient already know IgA deficiency document antibody IgA . 4 . Patient currently participate another interventional clinical study participate past 1 month prior study inclusion . 5 . Patient pregnant . 6 . Use AngiotensinConvertingEnzymeinhibitors within 72 hour start first infusion episode plan use medication study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Octaplas</keyword>
</DOC>